Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Gene therapy for the long term treatment of wet AMD

Age-related macular degeneration (AMD) is the most common cause of visual impairment in elderly populations of the developed world,1 and neovascular AMD (wet AMD) accounts for 90% of severe vision loss in patients with AMD. Wet AMD is associated with the upregulation of vascular endothelial growth factor (VEGF), which promotes angiogenesis and vascular permeability.2 Recently, therapies using recombinant anti-VEGF antibody fragments (eg, ranibizumab, bevacizumab, and aflibercept)3–5 to inhibit VEGF activity have shown that wet AMD can be treated successfully.